Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  BioLineRX Ltd.    BLRX   IL0011015182

BIOLINERX LTD. (BLRX)
My previous session
Most popular
Delayed Quote. Delayed  - 01/17 10:24:38 am
222.5 ILa   -0.98%
2012US HOT STOCK FUTURES : Hot stocks to watch
DJ
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
01/13/2019 01/14/2019 01/15/2019 01/16/2019 01/17/2019 Date
223(c) 219.6(c) 209.7(c) 224.7(c) 220.8(c) Last
139 422 153 649 327 057 781 921 309 012 Volume
+6.75% -1.52% -4.51% +7.15% -1.74% Change
More quotes
Company
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to... 
More about the company
Latest news on BIOLINERX LTD.
2018BIOLINERX : Begins Triple Combination Arm of Phase 2a Pancreatic Cancer Trial
AQ
2018MERCK AND : Results of triple combination arm of BL-8040, KEYTRUDA® and chemoth..
AQ
2018BIOLINERX : Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KE..
PR
2018BIOLINERX : to Host Investor and Analyst Breakfast Meeting on December 11, 2018 ..
PU
2018BIOLINERX : Announces Receipt of FDA Biological Product Designation for Novel Ca..
PR
2018MERCK AND : BioLineRx Reports Significant Progress Across Oncology Programs and ..
AQ
2018BIOLINERX : Reports Significant Progress Across Oncology Programs and Provides T..
PR
2018BIOLINERX : Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage..
PU
2018Palatin Technologies, Inc. - Immunotherapy Market Value Grows as the Treatmen..
AQ
2018BIOLINERX : Reports Second Quarter 2018 Financial Results
PR
More news
Analyst Recommendations on BIOLINERX LTD.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart BIOLINERX LTD.
Duration : Period :
BioLineRX Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOLINERX LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Managers
NameTitle
Philip Adam Serlin Chief Executive Officer & Head-Investor Relations
Aharon Schwartz Chairman
Mali Zeevi Chief Financial Officer
Abi Vainstein-Haras Vice President-Clinical Development
Sorani Ella Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOLINERX LTD.37.11%69
IQVIA HOLDINGS INC6.82%25 444
CELLTRION, INC.--.--%22 863
LONZA GROUP8.95%20 746
INCYTE CORPORATION23.32%16 688
SEATTLE GENETICS, INC.29.92%11 878